Ainos (AIMD) announced progress in advancing its oral interferon drug platform, Veldona in the rare disease space. The Taiwan FDA has approved the company’s clinical trial for human immunodeficiency virus-related oral warts, while Institutional Review Board clearance has been granted for its upcoming Sjogren’s Syndrome study. The upcoming Taiwan trials will be conducted using the company’s next-generation Veldona formulation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIMD: